[Introduction]

Med Clin (Barc). 2013 Sep:141 Suppl 2:1-2. doi: 10.1016/S0025-7753(13)70055-1.

[Article in Spanish]

Author

Santiago Durán García¹

Affiliation

¹ Departamento de Medicina, Facultad de Medicina, Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de Valme, Sevilla, España; European Association for the Study of Diabetes, American Diabetes Association, Sociedad Española de Endocrinología y Nutrición, Sociedad Española de Diabetes, Sociedad Andaluza de Endocrinología y Nutrición, Sociedad Española para el Estudio de la Obesidad. Electronic address: sduran@duransanz.com.

PMID: 24444516
DOI: 10.1016/S0025-7753(13)70055-1

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Benzhydryl Compounds / therapeutic use
Biological Transport, Active / drug effects
Canagliflozin
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism
Glucose / metabolism
Glucosides / therapeutic use
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use*
Kidney Tubules, Proximal / metabolism
Sodium-Glucose Transporter 1 / physiology
Sodium-Glucose Transporter 2 / physiology
Sodium-Glucose Transporter 2 Inhibitors
Thiophenes / therapeutic use

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
SLC5A1 protein, human
SLC5A2 protein, human
Sodium-Glucose Transporter 1
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Thiophenes
Canagliflozin
dapagliflozin
empagliflozin
Glucose